Journal
CHEMICAL RECORD
Volume 15, Issue 3, Pages 616-635Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/tcr.201402100
Keywords
boron; boronic acids; carboranes; drug design; inhibitors
Categories
Funding
- Grants-in-Aid for Scientific Research [26293007, 26102721] Funding Source: KAKEN
Ask authors/readers for more resources
The use of the element boron, which is not generally observed in a living body, possesses a high potential for the discovery of new biological activity in pharmaceutical drug design. In this account, we describe our recent developments in boron-based drug design, including boronic acid containing protein tyrosine kinase inhibitors, proteasome inhibitors, and tubulin polymerization inhibitors, and ortho-carborane-containing proteasome activators, hypoxia-inducible factor 1 inhibitors, and topoisomerase inhibitors. Furthermore, we applied a closo-dodecaborate as a water-soluble moiety as well as a boron-10 source for the design of boron carriers in boron neutron capture therapy, such as boronated porphyrins and boron lipids for a liposomal boron delivery system.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available